摘要
目的探讨肾上腺能α_(1A)-受体阻滞剂与5α-还原酶抑制剂联用治疗良性前列腺增生症(benign prostatic hyperplasia,BPH)的疗效。方法选取我院2015年1月—2017年1月收治良性前列腺增生症患者为研究对象,对照组50例患者口服盐酸坦洛新缓释胶囊,观察组50例患者在对照组基础上口服爱普列特,对比两组患者治疗前后前列腺特异性抗原、膀胱残余尿量、前列腺体积、生活质量、前列腺症状以及不良反应发生率。结果治疗前两组患者前列腺特异性抗原、膀胱残余尿量、前列腺体积、QOL、IPSS评分对比差异无统计学意义(P>0.05);治疗后两组患者膀胱残余尿量、IPSS评分均明显下降,QOL显著升高,但两组间对比差异无统计学意义(P> 0.05);治疗后观察组患者前列腺体积明显小于对照组,差异具有统计学意义(P <0.05)。观察组患者不良反应发生率20.00%,稍高于对照组14.00%,但是对比差异无统计学意义(P> 0.05)。结论两种药物联合使用效果更好,能缩小前列腺体积,改善临床症状,达到标本兼治效果,且安全性高。
Objective To investigate the efficacy of adrenalin alpha1Areceptor blocker combined with 5 alpha reductase inhibitor in the treatment of benign prostatic hyperplasia(BPH).Methods 100 patients with BPH in our hospital from January 2015 to January 2017 were selected as the research object.50 patients in the control group were treated with tamloxine hydrochloride sustained release capsule.50 patients in the observation group were treated with epristeride on the basis of the control group.The prostate specific antigen,residual urine volume of bladder and prostate body,quality of life,prostatic symptoms and incidence of adverse reactions were compared before and after treatment.Results There was no significant difference in PSA,residual urine volume,prostate volume,QOL and IPSS scores between the two groups before treatment(P >0.05),and The bladder residual urine volume and IPSS scores of the two groups decreased significantly after treatment,QOL increased significantly.but there was no significant difference between the two groups(P >0.05).After treatment,the prostate volume of the observation group was significantly smaller than that of the control group(P<0.05).The incidence of adverse reactions in the observation group was 20.00%,slightly higher than 14.00%in the control group,but there was no significant difference between the two groups(P >0.05).Conclusion The combined use of the two drugs is more effective,can reduce prostate volume,improve clinical symptoms,achieve the effect of both symptoms and symptoms,and high safety.
作者
王斌
肖明艳
WANG Bin;XIAO Mingyan(Department of Urology,Yunyang District People's Hospital of Shiyan City,Shiyan Hubei 442500,China;Department of Respiratory Medicine,Yunyang District People's Hospital of Shiyan City,Shiyan Hubei 442500,China)
出处
《中国继续医学教育》
2019年第5期129-131,共3页
China Continuing Medical Education
